Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trial.

British journal of haematology·2025
Same author

Efficacy and safety of luspatercept in non-transfusion-dependent β-thalassemia: long-term results from the BEYOND study.

Blood advances·2025
Same author

TIF Guidelines for the Management of Transfusion-Dependent β-Thalassemia.

HemaSphere·2025
Same author

Bone mineral density in adult thalassaemias: a retrospective longitudinal study.

Nuclear medicine communications·2024
Same author

Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency.

Blood advances·2024
Same author

Anesthetic Agents in Operations for Gunshot Wounds.

Western journal of medicine and surgery·2024
Same journal

Compound Heterozygous Hemoglobin Minneapolis-Laos and Codon 41/42 (-TTCT) in a Thai Female Adult: A Case Report and Literature Review.

Hemoglobin·2026
Same journal

Hb F-SickKids (<i>HBG2</i>: C.308A > G): A Novel γ-Globin Variant Associated with Transient Neonatal Cyanosis.

Hemoglobin·2026
Same journal

Pyruvate Kinase Activation in the Management of Thalassemia and Sickle Cell Disease.

Hemoglobin·2026
Same journal

Genotypic Characterization of Hemoglobinopathies in Azerbaijan: A Review of 10 Years at a Referral Center.

Hemoglobin·2026
Same journal

Successful Management of Transfusion-Dependent Unstable Hemoglobin Perth with Splenectomy: First Report from Iran and Literature Review.

Hemoglobin·2026
Same journal

Unstable Hemoglobin Variants: Molecular Mechanisms, Clinical Phenotypes, and a Practical Diagnostic and Management Approach.

Hemoglobin·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

Revealing the Ferroptotic Phenotype of Medulloblastoma
04:01

Revealing the Ferroptotic Phenotype of Medulloblastoma

Published on: March 15, 2024

Deferasirox: an update.

John B Porter1

  • 1Department of Haematology, University College London, London, UK. j.porter@ucl.ac.uk

Hemoglobin
|December 17, 2009
PubMed
Summary
This summary is machine-generated.

Deferasirox (DFS) is effective and safe for managing iron overload in patients with anemia. Long-term studies show dose-dependent iron reduction and manageable side effects, improving patient outcomes.

More Related Videos

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
05:36

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Published on: February 23, 2024

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
09:21

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts

Published on: February 23, 2024

Related Experiment Videos

Last Updated: Jun 17, 2026

Revealing the Ferroptotic Phenotype of Medulloblastoma
04:01

Revealing the Ferroptotic Phenotype of Medulloblastoma

Published on: March 15, 2024

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
05:36

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Published on: February 23, 2024

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
09:21

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts

Published on: February 23, 2024

Area of Science:

  • Hematology
  • Pharmacology
  • Clinical Medicine

Background:

  • Iron overload is a significant complication in patients with transfusion-dependent anemias.
  • Effective chelation therapy is crucial for managing excess iron and preventing organ damage.

Purpose of the Study:

  • To summarize cumulative data on the efficacy and safety of deferasirox (DFS) in patients with transfusion-dependent anemias.
  • To analyze the relationship between DFS dose, iron excretion, tolerability, and clinical outcomes.

Main Methods:

  • Prospective studies and large-scale trials (e.g., EPIC) involving over 3,000 patients.
  • Assessment of liver iron concentration (LIC), serum ferritin, and cardiac T2* to measure iron levels.
  • Monitoring of adverse events, including skin rash, gastrointestinal disturbances, and serum creatinine changes.

Main Results:

  • DFS effectively reduces body iron, as indicated by decreased LIC and serum ferritin levels.
  • Doses up to 30 mg/kg/day have been safely administered to over 200 patients without increased adverse events.
  • Significant reduction in cardiac iron was observed in patients with mild to moderate myocardial iron loading.

Conclusions:

  • Deferasirox is an effective and generally well-tolerated treatment for iron overload in transfusion-dependent anemias.
  • Long-term use of DFS demonstrates sustained efficacy and a manageable safety profile.
  • DFS therapy can lead to significant improvements in iron reduction and cardiac iron levels.